Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 794,664 shares at $3.20 ($2.5M) on 2024-08-13, disclosed to the SEC on 2024-08-14.
Scheduled sale ($2.5M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.13 | 1,600 | $5K | 0.2% |
| 2 | $3.20 | 394,664 | $1.3M | 49.7% |
| 3 | $3.20 | 394,664 | $1.3M | 49.7% |
| 4 | $3.25 | 3,736 | $12K | 0.5% |
| Total | $3.20 avg | 794,664 | $2.5M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |